HYDERGINE
LOE ApproachingNDAORALTABLET
Approved
Dec 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDERGINE is an oral small-molecule tablet approved in 1977 by Novartis for unspecified indications. The mechanism of action and pharmacologic class are not publicly detailed in available data. This legacy product represents a mature therapeutic asset with significant historical market presence.
LOE Approaching
HYDERGINE faces moderate competitive pressure (30%) as it approaches loss of exclusivity, signaling potential downsizing or transition roles within the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYDERGINE in its LOE-approaching phase offers limited growth opportunity but provides valuable experience managing mature product transitions and competitive defense strategies. This role is best suited for professionals interested in portfolio rationalization, life-cycle extension tactics, or transition planning.
Brand ManagerField Sales Representative
Worked on HYDERGINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.